Seeking Alpha

The FDA's attempts to expedite drug approval may have undermined safety, an article in the...

The FDA's attempts to expedite drug approval may have undermined safety, an article in the Journal of the American Medical Association says. The authors, Thomas Moore and Curt Furberg, point to problems with Novartis' (NVS) Gilenya drug for multiple sclerosis, AstraZeneca's (AZN) Caprelsa for thyroid cancer and Boehringer Ingelheim's Pradaxa for stroke prevention.
Comments (2)
  • chopchop0
    , contributor
    Comments (3650) | Send Message
     
    Make the process longer and then people will complain about how expensive new drugs are, when they don't realize it can cost hundreds of millions of dollars to develop and test the safety and efficacy of many of these novel compounds.
    5 Sep 2012, 10:19 AM Reply Like
  • Jolt1
    , contributor
    Comments (6) | Send Message
     
    Furberg, the gadfly, is back at it once more.
    5 Sep 2012, 02:52 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs